Canaccord analyst Michelle Gilson lowered the firm’s price target on Homology Medicines to $7 from $19 and keeps a Buy rating on the shares. The analyst said the target reduction was due to given the increased risk related to the clinical hold and substantial changes to the dosing protocol.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FIXX:
- Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
- Homology Medicines reports Q4 EPS (60c), consensus (50c)
- Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
- Homology Medicines announces promotion of Jordan to CMO
- Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer